- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.07. | Liminatus plans to invest up to $500 million in BNB coin | 3 | Investing.com | ||
| 28.07. | Liminatus Pharma Inc. to Launch "American BNB Strategy" Subsidiary and Target Up To $500 Million Fund for BNB Investment as Part of Crypto Market Initiative | 2 | GlobeNewswire (USA) | ||
| 25.07. | Liminatus Pharma Inc. Evaluates Formation of Digital Asset Investment Vehicle Targeting Up To $500 Million in Capital Strategies | 182 | GlobeNewswire (Europe) | LA PALMA, Calif., July 25, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 24.07. | Liminatus Pharma stock soars after engaging Digital Offering for capital raise | 2 | Investing.com | ||
| 24.07. | Pre-market Movers: Sadot Group, Community Health Systems, Liminatus Pharma, MaxLinear, Incannex Healthcare | 568 | AFX News | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.10 A.M. ET).In the Green Liminatus Pharma, Inc. (LIMN) is up over 25% at... ► Artikel lesen | |
| 24.07. | Liminatus Pharma Inc. Takes Next Step in Evaluating Digital Asset-Linked Capital Strategy | 1 | GlobeNewswire (USA) | ||
| 22.07. | Liminatus gains amid review to consider digital assets for treasury management | 2 | Seeking Alpha | ||
| LIMINATUS PHARMA Aktie jetzt für 0€ handeln | |||||
| 22.07. | Liminatus Pharma explores digital assets for treasury management | 1 | Investing.com | ||
| 22.07. | Liminatus Pharma Inc.: Liminatus Pharma, Inc. Initiates Strategic Review of Blockchain-Integrated Treasury Strategy | 133 | GlobeNewswire (Europe) | LA PALMA, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Liminatus Pharma, Inc. (NASDAQ: LIMN), a preclinical-stage biopharmaceutical company dedicated to the development of targeted cancer immunotherapies... ► Artikel lesen | |
| 11.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 03.07. | Liminatus Pharma bildet Konsortium für Bauchspeicheldrüsenkrebs-Diagnosekit | 1 | Investing.com Deutsch | ||
| 03.07. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 24.06. | Liminatus Pharma files to sell 6.9M shares of common stock | 2 | Seeking Alpha | ||
| 24.06. | Liminatus Pharma, Inc. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 24.06. | Liminatus Pharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.06. | Pre-market Movers: Creative Global Technology, Liminatus Pharma, CureVac, Jupiter Neurosciences, Tonix Pharmaceuticals | 639 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.05 A.M. ET).In the Green Creative Global Technology Holdings Limited (CGTL)... ► Artikel lesen | |
| 05.06. | Liminatus Pharma stock gains on regaining compliance with Nasdaq | 1 | Seeking Alpha | ||
| 05.06. | Liminatus Pharma-Aktien steigen nach Nasdaq-Compliance-Meldung | 5 | Investing.com Deutsch | ||
| 05.06. | Liminatus Pharma shares soar on Nasdaq compliance news | 1 | Investing.com | ||
| 05.06. | Pre-market Movers: Liminatus Pharma, ZenaTech, Ctrl Group, ZJK Industrial, Cibus | 929 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.50 A.M. ET).In the Green Liminatus Pharma, Inc. (LIMN) is up over 83% at $23.29.
ZenaTech... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| TENAYA THERAPEUTICS | 0,668 | 0,00 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Enrollment Complete in Cohorts 1 and 2 of MyPEAK-1 Phase 1b/2 Trial of TN-201 for MYBPC3-associated HCM; Positive DSMB Safety Review Enables Enrollment of Expansion Cohorts Cohort 1 of RIDGE-1 Phase... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 47,520 | 0,00 % | Aktien New York: Erholungspfad wieder aufgenommen - Apple ziehen stark an | NEW YORK (dpa-AFX) - Die US-Börsen haben am Mittwoch nach dem etwas schwächeren Vortag wieder den Weg nach oben eingeschlagen. Für Bewegung sorgten positiv aufgenommene Nachrichten zu Apple sowie Unternehmensberichte.... ► Artikel lesen | |
| QIAGEN | 41,095 | -1,59 % | Qiagen NV-Aktie mit Kursgewinnen (43,155 €) | Im Plus liegt derzeit die Qiagen NV-Aktie . Der jüngste Kurs betrug 43,16 Euro. Im Wertpapierhandel hat sich heute das Wertpapier von Qiagen NV zwischenzeitlich um 0,90 Prozent verteuert. Der Kurs des... ► Artikel lesen | |
| NUVALENT | 72,16 | 0,00 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline and Business Achievements, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2025 Financial Results | Initiated rolling NDA submission for zidesamtinib for TKI pre-treated patients with advanced ROS1-positive NSCLC, with target completion in the third quarter of... ► Artikel lesen | |
| DYNE THERAPEUTICS | 11,190 | -3,45 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) | - Data from the DELIVER registrational expansion cohort is expected in late 2025, with a potential BLA submission for U.S. accelerated approval anticipated in early 2026 - WALTHAM, Mass., Aug.... ► Artikel lesen | |
| DISC MEDICINE | 57,07 | -3,27 % | Disc Medicine GAAP EPS of -$1.58 | ||
| EVOTEC | 6,688 | +2,80 % | Vom Labor zur Listung: Diese Technologie könnte die Getränkeindustrie umkrempeln! | ||
| KINIKSA PHARMACEUTICALS | 33,110 | 0,00 % | Gold Fields, Kiniksa Join Best Stock Lists As They Defy Slump And Shares Pop: See New Names On IBD 50, IPO Leaders And More | ||
| ADMA BIOLOGICS | 16,740 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
| BIONTECH | 96,35 | +0,84 % | Ihre wichtigsten Termine: Tyson Foods, Biontech, Adtran, Loews, VDMA und Stabilus stehen heute im Fokus! | © Foto: UnsplashGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 07:00 Uhr, Luxemburg:... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 12,950 | -4,18 % | Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | - Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 2,945 | 0,00 % | Sana Biotechnology prices $75 million public offering at $3.35 per share | ||
| KEROS THERAPEUTICS | 13,360 | 0,00 % | Keros Therapeutics, Inc.: Keros to Exclusively Prioritize the Clinical Advancement of KER-065 | Company Discontinuing Development of Cibotercept (KER-012) Announces Board and Leadership Changes Designed to Support Streamlined Operational Structure and Strategic Realignment LEXINGTON, Mass.... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter 2025 Financial Results and Provides Business Update | SALT LAKE CITY, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,140 | 0,00 % | Arcutis outlines sustained ZORYVE growth with 28% sequential revenue expansion and eyes cash flow breakeven in 2026 |
LIMINATUS PHARMA INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 4,795 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LIMINATUS PHARMA INC finden Sie auf Wallstreet Online.